Horiike Atsushi

Prof. Dr. Horiike Atsushi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
RORyotaro Ohkuma
Ryotaro Ohkuma
KIKatsuaki Ieguchi
Katsuaki Ieguchi
MWMakoto Watanabe
Makoto Watanabe
DTDaisuke Takayanagi
Daisuke Takayanagi
TGTsubasa Goshima
Tsubasa Goshima
Satoshi WADASatoshi WADA
Satoshi WADA
Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to predict the therapeutic effect of ICIs. Therefore, this study investigated the clinical implications of plasma levels of soluble anti-programmed death-1 (sPD-1) in patients with cancer treated with ICIs. In total, 22 patients (13 with non-small-cell lung carcinoma, 8 with gastric cancer, and 1 with bladder cancer) were evaluated for sPD-1 concentration using enzyme-linked immunosorbent assays for diagnostic and anti-PD-1 antibody analyses. sPD-1 levels were low before the administration of anti-PD-1 antibodies. After two and four cycles of anti-PD-1 antibody therapy, sPD-1 levels significantly increased compared with pretreatment levels (p = 0.0348 vs. 0.0232). We observed an increased rate of change in plasma sPD-1 concentrations after two and four cycles of anti-PD-1 antibody therapy that significantly correlated with tumor size progression (p = 0.024). sPD-1 may be involved in resistance to anti-PD-1 antibody therapy, suggesting that changes in sPD-1 levels can identify primary ICI non-responders early in treatment. Detailed analysis of each cancer type revealed the potential of sPD-1 as a predictive biomarker of response to ICI treatment in patients with cancer.

10 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
リスリサコ スズキ
リサコ スズキ
RORyotaro Ohkuma
Ryotaro Ohkuma
MWMakoto Watanabe
Makoto Watanabe
EMEmiko Mura
Emiko Mura
TTToshiaki Tsurui
Toshiaki Tsurui
Satoshi WADASatoshi WADA
Satoshi WADA
Background/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; however, their efficacy varies among patients. Eosinophils have been reported as prognostic markers in chemotherapy-treated pancreatic cancer; however, these studies are limited mainly to single cancer types and relatively small cohorts. Therefore, we aimed to examine the relationship between eosinophil count and the effectiveness of ICIs across various cancer types. Methods: We retrospectively analyzed 138 patients treated with ICI monotherapy, ICI plus chemotherapy, or chemotherapy alone at our institution between December 2015 and September 2024. Peripheral blood parameters, including eosinophil counts and albumin levels, were collected at baseline and after two cycles of treatment. Associations between overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analysis and Cox proportional hazards regression. Results: In the ICI monotherapy group, patients with higher baseline eosinophil counts had significantly longer OS (HR 0.26, p = 0.007) and PFS (HR 0.30, p = 0.005). No significant associations were observed between the ICI plus chemotherapy and chemotherapy-alone groups. Changes in eosinophil counts between baseline and after two cycles were not associated with outcomes in any group. Conclusions: Baseline eosinophil counts were significantly associated with survival outcomes in patients receiving ICI monotherapy and may serve as a promising predictive biomarker.

18 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MWMakoto Watanabe
Makoto Watanabe
KIKatsuaki Ieguchi
Katsuaki Ieguchi
TSTakashi Shimizu
Takashi Shimizu
RORyotaro Ohkuma
Ryotaro Ohkuma
リスリサコ スズキ
リサコ スズキ
Satoshi WADASatoshi WADA
Satoshi WADA
Background/Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, reliable biomarkers of therapeutic efficacy remain limited. We investigated the clinical utility of plasma WFDC2 levels in patients receiving anti-PD-1 antibody treatment. Methods: Twenty-one patients with non-small cell lung, gastric, or bladder cancer received nivolumab or pembrolizumab. Plasma WFDC2 concentrations were measured by ELISA before ICI treatment (pre-ICI) and after two and four treatment cycles. Associations between WFDC2 expression changes and overall survival (OS), progression-free survival (PFS), and tumor progression were assessed. ROC curve analyses compared the predictive performance of WFDC2, soluble PD-L1 (sPD-L1), soluble PD-1 (sPD-1), and their combinations, with the area under the curve (AUC) evaluating predictive accuracy. Results: Levels of WFDC2 pre-ICI and those after two cycles were significantly higher than levels in healthy donors. However, no significant differences in WFDC2 levels were found between the time points during treatment. Greater increases in WFDC2 levels were significantly correlated with shorter OS (p = 0.002), shorter PFS (p = 0.037), and tumor progression (p = 0.003). ROC analysis revealed that WFDC2 achieved a higher AUC (0.700) than sPD-L1 (0.538) or sPD-1 (0.650). Combining biomarkers improved the predictive accuracy, with sPD-L1 plus WFDC2 showing the highest AUC (0.825). Conclusions: Serial increases in plasma WFDC2 are associated with poor clinical outcomes, highlighting its potential as a biomarker. Baseline plasma WFDC2 outperformed sPD-L1 and sPD-1 diagnostically. These findings should be interpreted as exploratory and hypothesis-generating, requiring confirmation in larger, tumor-specific cohorts with multivariate adjustment. WFDC2 represents a promising minimally invasive biomarker for the early identification of patients unlikely to benefit from ICI therapy.

15 October 2026
Verified
Other
Open access
HAHoriike Atsushi
Horiike Atsushi
HWHiroshi Wakui
Hiroshi Wakui
SSShunichi Sugawara
Shunichi Sugawara
YMYuji Minegishi
Yuji Minegishi
STSadatomo Tasaka
Sadatomo Tasaka
TTTakuya Tsunoda
Takuya Tsunoda
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial

11 October 2026 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
RORyotaro Ohkuma
Ryotaro Ohkuma
TTToshiaki Tsurui
Toshiaki Tsurui
TITomoyuki Ishiguro
Tomoyuki Ishiguro
GIGo Ikeda
Go Ikeda
MSMasahiro Shimokawa
Masahiro Shimokawa
HAHoriike Atsushi
Horiike Atsushi
Central nervous system germinoma is highly curable, but very late relapse and chronic endocrine sequelae can complicate salvage treatment. Herein, we report a 22-year-old man with central diabetes insipidus and panhypopituitarism who developed biopsy-proven pure germinoma in the right intraorbital optic nerve 12 years after treatment for childhood suprasellar germinoma. The optic nerve lesion was outside the initial irradiation field. A hemorrhagic right middle cerebellar peduncle lesion was radiographically suspicious but unbiopsied; angiography showed no detectable vascular lesion. During ifosfamide, cisplatin, and etoposide salvage chemotherapy, symptomatic grade 4 hypotonic hyponatremia developed (serum sodium 118.4 mEq/L; osmolality 236 mOsm/kg). On rechallenge, recorded urine output rose from 1.40 L/day on cycle 2 day 0 to 4.25 L/day on day 3 and 9.75 L/day on day 4, accompanied by high spot urinary sodium concentrations. Desmopressin, hydrocortisone, and levothyroxine were continued. Because oral intake, intravenous volumes, net balance, objective volume status, and fractional urate excretion were unavailable, the episode was classified as a chemotherapy-associated mixed sodium–water disturbance with a suspected salt-wasting component rather than confirmed renal salt wasting. Hypertonic saline, isotonic fluids, oral salt, and serial serum/urine monitoring were used. Recurrent toxicity prompted discontinuation of cisplatin and ifosfamide and a switch to carboplatin plus etoposide. The high-output pattern was attenuated, although grade 3 hyponatremia persisted. This supportive strategy enabled completion of curative-intent chemotherapy and craniospinal irradiation. At the 1-year imaging assessment, complete response was maintained.

27 July 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
HAHoriike Atsushi
Horiike Atsushi
HWHiroshi Wakui
Hiroshi Wakui
SSShunichi Sugawara
Shunichi Sugawara
YMYuji Minegishi
Yuji Minegishi
STSadatomo Tasaka
Sadatomo Tasaka
TTTakuya Tsunoda
Takuya Tsunoda
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. Patients and Methods: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The primary endpoint was the investigator-assessed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The sample comprised 50 patients (38 men, 12 women; median age, 72 years; range, 51–90 years). The ORR was 76% (95% confidence interval, 61.9–86.9; P < 0.0001), with complete and partial response rates of 2% and 74%, respectively. Moreover, 10% and 8% of the patients had stable and progressive disease, respectively, whereas 6% could not be evaluated. The median PFS was 15.7 months, whereas the median OS was not reached at the time of analysis. The most common treatment-related adverse events were rash (64%) and hypomagnesemia (60%). Grade 3 interstitial lung disease occurred in five patients (10%), and grade 5 cardiac arrest occurred in one patient (2%). Conclusions: The pembrolizumab and necitumumab combination exhibited a promising ORR of 76% with a manageable safety profile in patients with NSCLC who had high PD-L1 expression. These findings highlight the need for further research on this regimen for patients with advanced NSCLC who have high PD-L1 expression.